Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Tacrolimus

Classification: B

Drug products: Protopic, Takrolimus Accord

ATC code: D11AH01

Substances: tacrolimus, tacrolimus monohydrate

Summary

Controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of tacrolimus are lacking.
 
The present evidence concerning differences between men and women is very limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No difference between men and women has been shown for transdermal absorption in general [1].

Effects

No studies with a clinically relevant sex analysis regarding effects of tacrolimus have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of tacrolimus have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2017-03-24

References

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-03-23.] länk

Authors: Maria Enghag

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson